Last updated: December 16, 2020
Sponsor: Forest Laboratories
Overall Status: Completed
Phase
1
Condition
Gastrointestinal Diseases And Disorders
Breast Feeding
Lactose Intolerance
Treatment
N/AClinical Study ID
NCT02220348
LIN-PK-01
Ages 18-45 Female
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Be a lactating female who has been actively breastfeeding or pumping for at least 4weeks
- Be already taking linaclotide therapeutically for Irritable Bowel Syndrome withConstipation (IBS-C) or Chronic Idiopathic Constipation (CIC)
- Weaning must not be underway
- Be willing to breastfeed or pump regularly during the study to maintain milk supplyand discontinue breastfeeding for the 24-hour period of breast milk collection
Exclusion
Exclusion Criteria:
- Clinically significant disease state in any body system, except for the indicationbeing treated with linaclotide
- Any structural abnormality of the gastrointestinal (GI) tract, or a disease orcondition that can affect GI motility
- Participation in any other clinical investigation using an experimental drug within 90days
Study Design
Total Participants: 7
Study Start date:
July 31, 2014
Estimated Completion Date:
May 31, 2019
Connect with a study center
University of Iowa
Iowa City, Iowa 52242
United StatesSite Not Available
Digestive Disease Specialists Inc (DDSI)
Oklahoma City, Oklahoma 73112
United StatesSite Not Available
Temple University Hospital
Philadelphia, Pennsylvania 19140
United StatesSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.